HC Wainwright Cuts OnKure Therapeutics (NASDAQ:OKUR) Price Target to $34.00

OnKure Therapeutics (NASDAQ:OKUR) had its target price reduced by HC Wainwright from $40.00 to $34.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

Several other equities research analysts also recently commented on the company. Leerink Partners began coverage on OnKure Therapeutics in a report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective for the company. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Price Performance

NASDAQ OKUR opened at $5.00 on Tuesday. OnKure Therapeutics has a one year low of $4.45 and a one year high of $20.00. The stock has a 50-day simple moving average of $5.48. The company has a market cap of $67.18 million, a P/E ratio of -0.41 and a beta of 0.28.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, equities research analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

A number of large investors have recently made changes to their positions in OKUR. Highbridge Capital Management LLC bought a new stake in shares of OnKure Therapeutics during the 4th quarter valued at about $3,438,000. Geode Capital Management LLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at approximately $659,000. Aisling Capital Management LP bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at approximately $762,000. Aldebaran Capital LLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at approximately $392,000. Finally, Renaissance Technologies LLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at approximately $408,000. 90.98% of the stock is currently owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.